Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGE DUVALL

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1073526604
CMS profile
138834
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,894.82

156 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,876.88 154
Education $17.94 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGE DUVALL

NPI 1073526604 · CMS profile ID 138834

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073526604?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGE DUVALL, NPI 1073526604, CMS profile ID 138834. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073526604?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GEORGE DUVALL, NPI 1073526604, CMS profile ID 138834. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073526604?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GEORGE DUVALL, NPI 1073526604, CMS profile ID 138834, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 156 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1073526604?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

156 matching records · $2,894.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 156 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 156.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $6.3605/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389447 CMS
AbbVie Inc. $18.7205/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389445 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.8605/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917267 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.6505/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917265 CMS
AbbVie Inc. $19.6204/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389443 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.0104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850163131 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.2304/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850203899 CMS
Janssen Biotech, Inc. $14.3304/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788996131 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.6904/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917263 CMS
Takeda Pharmaceuticals U.S.A., Inc. $9.8204/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917261 CMS
Nestle HealthCare Nutrition Inc. $17.1604/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820891409 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.1604/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917259 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.6104/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917257 CMS
AbbVie Inc. $16.5504/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389441 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.9004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917255 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.5904/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849933847 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.7704/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850022769 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.6704/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850321937 CMS
AbbVie Inc. $10.1503/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389439 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.9003/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850372395 CMS
AbbVie Inc. $15.3903/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389437 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.6003/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917253 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.5103/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917251 CMS
Braintree Laboratories, Inc. $15.1503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805243889 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.5403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849978343 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.7303/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917249 CMS
Nestle HealthCare Nutrition Inc. $14.0703/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820891405 CMS
AbbVie Inc. $16.6203/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389433 CMS
AbbVie Inc. $21.3903/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389435 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.8603/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850301201 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.6103/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850031843 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.5703/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850227227 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.9303/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917247 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.7103/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849989359 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.6803/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850228889 CMS
AbbVie Inc. $18.2902/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389431 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.5402/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850310759 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.9602/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850319415 CMS
AbbVie Inc. $15.3802/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389429 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.2702/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917245 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.1201/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917243 CMS
AbbVie Inc. $24.5201/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389427 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.6101/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819917241 CMS
AbbVie Inc. $4.3701/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794389425 CMS
Nestle HealthCare Nutrition Inc. $15.4401/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820891401 CMS
RedHill Biopharma Inc. $11.8701/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799917783 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.8501/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849963707 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.7501/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849991677 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.0101/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850139187 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.0701/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850360021 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,698.09 131
PY2020 $22,539.83 92
PY2021 $2,894.82 156
PY2022 $4,145.69 139
PY2023 $3,143.01 154
PY2024 $4,941.59 155
PY2025 $2,390.03 116

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $4,098,178.59 730
PY2024 Recipient $1,328.99 7
PY2024 Principal investigator $5,038,555.15 1,258
PY2023 Recipient $519.93 1
PY2023 Principal investigator $3,649,653.73 557
PY2022 Principal investigator $1,811,459.74 284
PY2021 Recipient $1,545.44 1
PY2021 Principal investigator $1,226,332.53 150
PY2020 Recipient $17,842.00 2
PY2020 Principal investigator $873,043.80 191
PY2019 Recipient $33,437.88 3
PY2019 Principal investigator $714,998.19 138

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

730 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $25,389.50 12/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187893640
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175288759
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290192
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290369
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290803
Principal investigator 1 Janssen Research & Development, LLC $12,084.00 12/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis? No dispute reported 06/30/2026 1175411467
Principal investigator 1 Janssen Research & Development, LLC $76.00 12/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175287909
Principal investigator 1 Janssen Research & Development, LLC $5,937.00 12/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288434
Principal investigator 1 Janssen Research & Development, LLC $3,687.00 12/26/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411516
Principal investigator 1 PFIZER INC. $1,173.00 12/23/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228813098
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 12/22/2025 Non-covered Recipient Entity
Tyler Research Institute Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226121389
Principal investigator 1 F. Hoffmann-La Roche AG $176.00 12/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674501
Principal investigator 1 F. Hoffmann-La Roche AG $11,165.00 12/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674509
Principal investigator 1 F. Hoffmann-La Roche AG $194.00 12/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674511
Principal investigator 1 F. Hoffmann-La Roche AG $9,011.00 12/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674524
Principal investigator 1 F. Hoffmann-La Roche AG $5,185.00 12/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674540
Principal investigator 1 F. Hoffmann-La Roche AG $414.00 12/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674545
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288385
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288500
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288508
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289178
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289215
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289426
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289825
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290159
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290177
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290470
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290756
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 12/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290872
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $373.00 12/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223289938
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 12/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223289940
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,564.40 12/18/2025 Non-covered Recipient Entity
Tyler Research Institute
A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1235992845
Principal investigator 1 Janssen Research & Development, LLC $184.00 12/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288130
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 12/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288247
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 12/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288276
Principal investigator 1 Janssen Research & Development, LLC $335.00 12/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288683
Principal investigator 1 Janssen Research & Development, LLC $184.00 12/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289142
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 12/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289625
Principal investigator 1 ABBVIE INC. $1,096.80 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202526848
Principal investigator 1 ABBVIE INC. $2,782.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202526860
Principal investigator 1 ABBVIE INC. $3,090.77 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202527684
Principal investigator 1 ABBVIE INC. $2,600.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202527884
Principal investigator 1 ABBVIE INC. $1,755.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202527886
Principal investigator 1 ABBVIE INC. $5,267.70 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202527888
Principal investigator 1 ABBVIE INC. $2,494.70 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202527890
Principal investigator 1 F. Hoffmann-La Roche AG $909.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674497
Principal investigator 1 F. Hoffmann-La Roche AG $1,242.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674505
Principal investigator 1 F. Hoffmann-La Roche AG $720.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674515
Principal investigator 1 F. Hoffmann-La Roche AG $194.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674520
Principal investigator 1 F. Hoffmann-La Roche AG $2,963.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674528
Principal investigator 1 F. Hoffmann-La Roche AG $686.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674531
Principal investigator 1 F. Hoffmann-La Roche AG $414.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674537
Principal investigator 1 F. Hoffmann-La Roche AG $4,001.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674542
Principal investigator 1 F. Hoffmann-La Roche AG $8,337.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674548
Principal investigator 1 F. Hoffmann-La Roche AG $878.00 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674551
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $949.55 12/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279 CD/UC Ph2 OLE No dispute reported 06/30/2026 1223289196
Principal investigator 1 ABBVIE INC. $13,571.15 12/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202526386
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287924
Principal investigator 1 Janssen Research & Development, LLC $343.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288139
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288155
Principal investigator 1 Janssen Research & Development, LLC $184.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288313
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288539
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288731
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288752
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288844
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288953
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288960
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289019
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289052
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289255
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289278
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289324
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289346
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289369
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289419
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289456
Principal investigator 1 Janssen Research & Development, LLC $343.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289495
Principal investigator 1 Janssen Research & Development, LLC $343.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289676
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 11/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290057
Principal investigator 1 ABBVIE INC. $894.90 11/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202525242
Principal investigator 1 Genentech, Inc. $42,171.00 11/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674701
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $373.00 11/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223288761
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,984.25 11/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223288763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $67.50 11/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223288765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,192.35 11/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223288767
Principal investigator 1 SANOFI US SERVICES INC. $85.00 11/24/2025 Non-covered Recipient Entity
Tyler Research Institute Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226121379
Principal investigator 1 ABBVIE INC. $5,456.90 11/21/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202525104
Principal investigator 1 ABBVIE INC. $10,632.80 11/21/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202525106
Principal investigator 1 Genentech, Inc. $690.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674704
Principal investigator 1 Genentech, Inc. $1,089.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674722
Principal investigator 1 Genentech, Inc. $414.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674776
Principal investigator 1 Genentech, Inc. $117.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674782
Principal investigator 1 Genentech, Inc. $439.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674802
Principal investigator 1 Genentech, Inc. $9,660.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674833
Principal investigator 1 Genentech, Inc. $7,998.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674838
Principal investigator 1 Genentech, Inc. $5,575.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674851
Principal investigator 1 Genentech, Inc. $255.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674860
Principal investigator 1 Genentech, Inc. $117.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674868
Principal investigator 1 Genentech, Inc. $329.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674880
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,888.76 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223288605
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $44.55 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223288621
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $393.96 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223288623
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,077.00 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223288625
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $262.54 11/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223288627
Principal investigator 1 PFIZER INC. $584.00 11/17/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228812401
Principal investigator 1 PFIZER INC. $2,471.00 11/17/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228812500
Principal investigator 1 PFIZER INC. $584.00 11/17/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228812511
Principal investigator 1 Genentech, Inc. $17,738.00 11/14/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674697
Principal investigator 1 ABBVIE INC. $7,545.60 11/13/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202524187
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $100,790.10 11/10/2025 Non-covered Recipient Entity
Tyler Research Institute, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244052569
Principal investigator 1 Genentech, Inc. $558.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674679
Principal investigator 1 Genentech, Inc. $117.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674686
Principal investigator 1 Genentech, Inc. $690.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674690
Principal investigator 1 Genentech, Inc. $819.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674694
Principal investigator 1 Genentech, Inc. $9,660.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674709
Principal investigator 1 Genentech, Inc. $576.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674712
Principal investigator 1 Genentech, Inc. $576.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674717
Principal investigator 1 Genentech, Inc. $2,361.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674724
Principal investigator 1 Genentech, Inc. $1,452.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674729
Principal investigator 1 Genentech, Inc. $264.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674732
Principal investigator 1 Genentech, Inc. $1,656.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674735
Principal investigator 1 Genentech, Inc. $88.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674739
Principal investigator 1 Genentech, Inc. $288.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674743
Principal investigator 1 Genentech, Inc. $927.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674747
Principal investigator 1 Genentech, Inc. $414.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674750
Principal investigator 1 Genentech, Inc. $19,993.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674754
Principal investigator 1 Genentech, Inc. $414.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674757
Principal investigator 1 Genentech, Inc. $6,914.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674762
Principal investigator 1 Genentech, Inc. $720.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674766
Principal investigator 1 Genentech, Inc. $176.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674769
Principal investigator 1 Genentech, Inc. $1,518.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674787
Principal investigator 1 Genentech, Inc. $1,085.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674790
Principal investigator 1 Genentech, Inc. $117.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674794
Principal investigator 1 Genentech, Inc. $720.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674798
Principal investigator 1 Genentech, Inc. $1,407.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674805
Principal investigator 1 Genentech, Inc. $9,660.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674809
Principal investigator 1 Genentech, Inc. $10,322.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674813
Principal investigator 1 Genentech, Inc. $1,133.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674818
Principal investigator 1 Genentech, Inc. $966.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674822
Principal investigator 1 Genentech, Inc. $1,756.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674825
Principal investigator 1 Genentech, Inc. $19,320.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674829
Principal investigator 1 Genentech, Inc. $662.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674840
Principal investigator 1 Genentech, Inc. $5,455.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674845
Principal investigator 1 Genentech, Inc. $219.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674857
Principal investigator 1 Genentech, Inc. $519.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674865
Principal investigator 1 Genentech, Inc. $369.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674872
Principal investigator 1 Genentech, Inc. $9,971.00 11/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674877
Principal investigator 1 ABBVIE INC. $13,398.75 11/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202523521
Principal investigator 1 ABBVIE INC. $10,099.35 11/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202522893
Principal investigator 1 ABBVIE INC. $8,106.35 11/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202522959
Principal investigator 1 Genentech, Inc. $144.00 11/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211674884
Principal investigator 1 Genentech, Inc. $11,527.00 11/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211674890
Principal investigator 1 ABBVIE INC. $1,096.80 11/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202520283
Principal investigator 1 ABBVIE INC. $9,306.10 11/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202521147
Principal investigator 1 ABBVIE INC. $4,050.00 11/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202521149
Principal investigator 1 Janssen Research & Development, LLC $5,937.00 11/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289779
Principal investigator 1 Janssen Research & Development, LLC $76.00 11/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289787
Principal investigator 1 Janssen Research & Development, LLC $1,780.00 11/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411436
Principal investigator 1 ABBVIE INC. $13,398.75 10/30/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202519727
Principal investigator 1 Genentech, Inc. $144.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674579
Principal investigator 1 Genentech, Inc. $117.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674581
Principal investigator 1 Genentech, Inc. $117.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674584
Principal investigator 1 Genentech, Inc. $10,011.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674587
Principal investigator 1 Genentech, Inc. $10,329.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674592
Principal investigator 1 Genentech, Inc. $9,660.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674597
Principal investigator 1 Genentech, Inc. $276.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674601
Principal investigator 1 Genentech, Inc. $234.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674612
Principal investigator 1 Genentech, Inc. $8,002.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674621
Principal investigator 1 Genentech, Inc. $552.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674627
Principal investigator 1 Genentech, Inc. $432.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674630
Principal investigator 1 Genentech, Inc. $117.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674635
Principal investigator 1 Genentech, Inc. $414.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674639
Principal investigator 1 Genentech, Inc. $288.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674643
Principal investigator 1 Genentech, Inc. $117.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674648
Principal investigator 1 Genentech, Inc. $15,961.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674655
Principal investigator 1 Genentech, Inc. $9,660.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674670
Principal investigator 1 Genentech, Inc. $288.00 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674674
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,246.19 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223287715
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,481.92 10/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223287717
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175287939
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287954
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288000
Principal investigator 1 Janssen Research & Development, LLC $5,937.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288054
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288269
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288370
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288410
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175288446
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288601
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175288633
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288722
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288774
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288914
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289404
Principal investigator 1 Janssen Research & Development, LLC $6,340.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175289699
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289758
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289795
Principal investigator 1 Janssen Research & Development, LLC $1,889.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289811
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289879
Principal investigator 1 Janssen Research & Development, LLC $343.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175289933
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289975
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290088
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290110
Principal investigator 1 Janssen Research & Development, LLC $76.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290140
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290212
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290235
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290406
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290462
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290531
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290554
Principal investigator 1 Janssen Research & Development, LLC $76.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290702
Principal investigator 1 Janssen Research & Development, LLC $184.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290733
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290817
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 10/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290920
Principal investigator 1 ABBVIE INC. $13,398.75 10/23/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202518261
Principal investigator 1 ABBVIE INC. $12,982.95 10/23/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202518277
Principal investigator 1 ABBVIE INC. $91,800.00 10/23/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202518279
Principal investigator 1 Genentech, Inc. $24,106.00 10/23/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674661
Principal investigator 1 PFIZER INC. $593.00 10/20/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228812371
Principal investigator 1 PFIZER INC. $4,040.00 10/20/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228812504
Principal investigator 1 PFIZER INC. $4,436.00 10/20/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228812517
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,661.03 10/16/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279 CD/UC Ph2 OLE No dispute reported 06/30/2026 1223287031
Principal investigator 1 ABBVIE INC. $1,057.50 10/09/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202514461
Principal investigator 1 ABBVIE INC. $879.60 10/09/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202515579
Principal investigator 1 ABBVIE INC. $19,775.30 10/09/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202515739
Principal investigator 1 Genentech, Inc. $4,518.00 10/09/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674652
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,063.50 10/09/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223286597
Principal investigator 1 Genentech, Inc. $34,280.00 10/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674606
Principal investigator 1 Genentech, Inc. $3,728.00 10/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674666
Principal investigator 1 Janssen Research & Development, LLC $3,553.00 10/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411505
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287991
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288081
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288257
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288307
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288377
Principal investigator 1 Janssen Research & Development, LLC $184.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288523
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288782
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289287
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289309
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289487
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289604
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289671
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289715
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289892
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289967
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290243
Principal investigator 1 Janssen Research & Development, LLC $184.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290426
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/29/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290477
Principal investigator 1 Janssen Research & Development, LLC $2,075.00 09/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175411447
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35,558.10 09/25/2025 Non-covered Recipient Entity
Tyler Research Institute, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244052567
Principal investigator 1 ABBVIE INC. $13,398.75 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202511430
Principal investigator 1 ABBVIE INC. $40,196.25 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202511464
Principal investigator 1 ABBVIE INC. $13,398.75 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202511466
Principal investigator 1 F. Hoffmann-La Roche AG $102,664.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674416
Principal investigator 1 F. Hoffmann-La Roche AG $1,380.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674426
Principal investigator 1 F. Hoffmann-La Roche AG $9,777.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674434
Principal investigator 1 F. Hoffmann-La Roche AG $1,359.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674446
Principal investigator 1 F. Hoffmann-La Roche AG $1,152.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674449
Principal investigator 1 F. Hoffmann-La Roche AG $513.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674462
Principal investigator 1 F. Hoffmann-La Roche AG $1,242.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674487
Principal investigator 1 F. Hoffmann-La Roche AG $28,980.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674491
Principal investigator 1 F. Hoffmann-La Roche AG $909.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674494
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,532.01 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223285656
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,096.00 09/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223285658
Principal investigator 1 Janssen Research & Development, LLC $76.00 09/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290132
Principal investigator 1 Janssen Research & Development, LLC $5,937.00 09/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290500
Principal investigator 1 Janssen Research & Development, LLC $76.00 09/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290642
Principal investigator 1 Janssen Research & Development, LLC $5,937.00 09/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290655
Principal investigator 1 Janssen Research & Development, LLC $5,576.00 09/15/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411511
Principal investigator 1 F. Hoffmann-La Roche AG $11,445.00 09/12/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674430
Principal investigator 1 F. Hoffmann-La Roche AG $2,346.00 09/12/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674438
Principal investigator 1 F. Hoffmann-La Roche AG $58,662.00 09/12/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674458
Principal investigator 1 F. Hoffmann-La Roche AG $3,726.00 09/12/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674478
Principal investigator 1 F. Hoffmann-La Roche AG $1,506.00 09/12/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,031.75 09/12/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223285337
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18,800.10 09/09/2025 Non-covered Recipient Entity
Tyler Research Institute, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244052565
Principal investigator 1 Janssen Research & Development, LLC $5,909.00 09/08/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411479
Principal investigator 1 ABBVIE INC. $17,850.00 09/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202509168
Principal investigator 1 ABBVIE INC. $26,797.50 09/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202509170
Principal investigator 1 ABBVIE INC. $2,494.70 09/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202507759
Principal investigator 1 ABBVIE INC. $4,426.40 09/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202507761
Principal investigator 1 ABBVIE INC. $2,988.00 09/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202508098
Principal investigator 1 PFIZER INC. $8,872.00 09/03/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228826918
Principal investigator 1 ABBVIE INC. $13,398.75 08/28/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202506383
Principal investigator 1 ABBVIE INC. $26,797.50 08/28/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202506385
Principal investigator 1 ABBVIE INC. $53,223.75 08/28/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202506387
Principal investigator 1 ABBVIE INC. $13,398.75 08/28/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202506393
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287984
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288070
Principal investigator 1 Janssen Research & Development, LLC $343.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288262
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288335
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288440
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288532
Principal investigator 1 Janssen Research & Development, LLC $343.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288586
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288648
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288741
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288829
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288923
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289038
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289077
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289199
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289221
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289228
Principal investigator 1 Janssen Research & Development, LLC $1,889.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289237
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289685
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289707
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289834
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289840
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289848
Principal investigator 1 Janssen Research & Development, LLC $184.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289863
Principal investigator 1 Janssen Research & Development, LLC $184.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289900
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289925
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290013
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290022
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290035
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290096
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290145
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290200
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290398
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290487
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290547
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290562
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290586
Principal investigator 1 Janssen Research & Development, LLC $343.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290595
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290618
Principal investigator 1 Janssen Research & Development, LLC $184.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290647
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290719
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290727
Principal investigator 1 Janssen Research & Development, LLC $343.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290778
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290839
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290864
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290938
Principal investigator 1 F. Hoffmann-La Roche AG $10,836.00 08/26/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674472
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,303.64 08/26/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223284587
Principal investigator 1 SANOFI US SERVICES INC. $4,250.00 08/25/2025 Non-covered Recipient Entity
Tyler Research Institute Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226121287
Principal investigator 1 F. Hoffmann-La Roche AG $1,026.00 08/21/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674421
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,394.77 08/21/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223284497
Principal investigator 1 Eli Lilly and Company $21,938.21 08/15/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187891468
Principal investigator 1 F. Hoffmann-La Roche AG $28,507.00 08/14/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674469
Principal investigator 1 SANOFI US SERVICES INC. $6,970.00 08/11/2025 Non-covered Recipient Entity
Tyler Research Institute Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226121276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $949.55 08/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279 CD/UC Ph2 OLE No dispute reported 06/30/2026 1223283943
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,859.05 08/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223283945
Principal investigator 1 ABBVIE INC. $7,600.80 08/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202501538
Principal investigator 1 ABBVIE INC. $2,494.70 08/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202501718
Principal investigator 1 ABBVIE INC. $17,346.70 08/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202501720
Principal investigator 1 Janssen Research & Development, LLC $2,525.00 08/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175411522
Principal investigator 1 ABBVIE INC. $12,723.75 07/31/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202500780
Principal investigator 1 F. Hoffmann-La Roche AG $80,690.00 07/31/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211674442
Principal investigator 1 F. Hoffmann-La Roche AG $37,469.00 07/31/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674466
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,286.47 07/31/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223283276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,905.00 07/31/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223283278
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $373.00 07/31/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223283280
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 07/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175288356
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 07/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175288852
Principal investigator 1 Janssen Research & Development, LLC $3,629.00 07/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290913
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175287894
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288148
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288321
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288516
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288994
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289070
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289540
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289739
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289911
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290081
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290711
Principal investigator 1 Janssen Research & Development, LLC $184.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290742
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 07/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290793
Principal investigator 1 F. Hoffmann-La Roche AG $39,570.00 07/22/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674475
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,918.42 07/22/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279 CD/UC Ph2 OLE No dispute reported 06/30/2026 1223282884
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,859.05 07/22/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223282886
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,804.95 07/17/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223282746
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,804.95 07/17/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223282748
Principal investigator 1 PFIZER INC. $1,747.00 07/11/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228826924
Principal investigator 1 PFIZER INC. $584.00 07/11/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228826931
Principal investigator 1 PFIZER INC. $2,471.00 07/11/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228827802
Principal investigator 1 F. Hoffmann-La Roche AG $28,090.00 07/10/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,079.00 07/10/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223282508
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,481.92 07/10/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223282510
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $28,948.50 07/10/2025 Non-covered Recipient Entity
Tyler Research Institute, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244052563
Principal investigator 1 ABBVIE INC. $16,692.75 07/08/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202497140
Principal investigator 1 Janssen Research & Development, LLC $5,281.00 07/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411411
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,031.75 07/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223282222
Principal investigator 1 ABBVIE INC. $7,029.10 07/02/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202494693
Principal investigator 1 ABBVIE INC. $10,804.70 07/02/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202494695
Principal investigator 1 ABBVIE INC. $4,680.65 07/02/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202494699
Principal investigator 1 ABBVIE INC. $7,450.00 07/02/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202496309
Principal investigator 1 ABBVIE INC. $112.20 07/02/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202496311
Principal investigator 1 ABBVIE INC. $13,315.85 07/02/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202496315
Principal investigator 1 Genentech, Inc. $348.00 07/02/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211674574
Principal investigator 1 Janssen Research & Development, LLC $3,629.00 06/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175288063
Principal investigator 1 Janssen Research & Development, LLC $6,340.00 06/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175288907
Principal investigator 1 Janssen Research & Development, LLC $343.00 06/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175289104
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175289120
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175289870
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290351
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288047
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288111
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288180
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288285
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288675
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288814
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289062
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289184
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289302
Principal investigator 1 Janssen Research & Development, LLC $2,632.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289464
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289548
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289731
Principal investigator 1 Janssen Research & Development, LLC $2,953.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289961
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290005
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290050
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290516
Principal investigator 1 Janssen Research & Development, LLC $2,632.00 06/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290930
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,109.14 06/24/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223281740
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,031.75 06/24/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223281742
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,079.00 06/24/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223281794
Principal investigator 1 Genentech, Inc. $24,353.00 06/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674568
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,165.93 06/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279 CD/UC Ph2 OLE No dispute reported 06/30/2026 1223281624
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,859.05 06/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223281654
Principal investigator 1 Janssen Research & Development, LLC $184.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288038
Principal investigator 1 Janssen Research & Development, LLC $184.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288199
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288456
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288593
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288668
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288947
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289096
Principal investigator 1 Janssen Research & Development, LLC $184.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289192
Principal investigator 1 Janssen Research & Development, LLC $184.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289340
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289513
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289917
Principal investigator 1 Janssen Research & Development, LLC $184.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290074
Principal investigator 1 Janssen Research & Development, LLC $2,230.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290334
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290455
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 06/18/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290762
Principal investigator 1 PFIZER INC. $2,471.00 06/18/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228829516
Principal investigator 1 PFIZER INC. $1,747.00 06/18/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228829858
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $949.55 06/12/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279 CD/UC Ph2 OLE No dispute reported 06/30/2026 1223281112
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,325.40 06/12/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223281114
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,079.00 06/12/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223281174
Principal investigator 1 Eli Lilly and Company $1,014.78 06/10/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187893638
Principal investigator 1 PFIZER INC. $1,173.00 06/09/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228829279
Principal investigator 1 ABBVIE INC. $5,955.80 06/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202488621
Principal investigator 1 ABBVIE INC. $318.50 06/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202488623
Principal investigator 1 ABBVIE INC. $1,588.80 06/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202489763
Principal investigator 1 ABBVIE INC. $3,398.40 06/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202489765
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $261,501.30 06/03/2025 Non-covered Recipient Entity
Tyler Research Institute, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244052561
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288103
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288208
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288219
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288623
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288937
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288971
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289245
Principal investigator 1 Janssen Research & Development, LLC $343.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289503
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290604
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 05/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290662
Principal investigator 1 Genentech, Inc. $17,066.00 05/27/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674564
Principal investigator 1 Janssen Research & Development, LLC $1,696.00 05/26/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411460
Principal investigator 1 Janssen Research & Development, LLC $2,770.00 05/23/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175411430
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,457.00 05/22/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223280134
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,303.64 05/22/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223280136
Principal investigator 1 Janssen Research & Development, LLC $5,576.00 05/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411442
Principal investigator 1 Genentech, Inc. $18,112.00 05/15/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,896.10 05/15/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223279830
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,488.75 05/15/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223279832
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,288.40 05/13/2025 Non-covered Recipient Entity
Tyler Research Institute, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244052559
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 05/12/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175287961
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 05/12/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288608
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 05/12/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288616
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289159
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289523
Principal investigator 1 Janssen Research & Development, LLC $184.00 05/12/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290205
Principal investigator 1 Janssen Research & Development, LLC $335.00 05/12/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290786
Principal investigator 1 Genentech, Inc. $14,908.00 05/08/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211674560
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,303.64 05/08/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223279168
Principal investigator 1 ABBVIE INC. $2,360.00 05/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202482837
Principal investigator 1 ABBVIE INC. $52,500.35 05/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202482839
Principal investigator 1 Celgene Corporation $4,922.00 05/07/2025 Non-covered Recipient Entity
Tyler Research Institute
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222307173
Principal investigator 1 ABBVIE INC. $282.50 05/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202481485
Principal investigator 1 ABBVIE INC. $17,454.90 05/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202481487
Principal investigator 1 ABBVIE INC. $18,883.90 05/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202481491
Principal investigator 1 ABBVIE INC. $2,787.20 05/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202481493
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $130,467.70 05/01/2025 Non-covered Recipient Entity
Tyler Research Institute, LLC
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) No dispute reported 06/30/2026 1244052537
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287947
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288097
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288122
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288162
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288172
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288203
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288392
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288400
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288492
Principal investigator 1 Janssen Research & Development, LLC $2,632.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288660
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288766
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288869
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288875
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288979
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288987
Principal investigator 1 Janssen Research & Development, LLC $2,953.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289003
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289011
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289127
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289150
Principal investigator 1 Janssen Research & Development, LLC $3,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289395
Principal investigator 1 Janssen Research & Development, LLC $3,228.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289412
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289530
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289566
Principal investigator 1 Janssen Research & Development, LLC $3,228.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289571
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289660
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289723
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289762
Principal investigator 1 Janssen Research & Development, LLC $3,228.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289856
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289988
Principal investigator 1 Janssen Research & Development, LLC $2,632.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290029
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290043
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290065
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290116
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290228
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290287
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290308
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290377
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290390
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290447
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290508
Principal investigator 1 Janssen Research & Development, LLC $343.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290770
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290882
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290904
Principal investigator 1 Janssen Research & Development, LLC $9,506.00 04/28/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,079.00 04/28/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223278684
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,394.77 04/23/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223278590
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/21/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175288087
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/21/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175288225
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 04/21/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175289361
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/21/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290281
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 04/21/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290634
Principal investigator 1 Janssen Research & Development, LLC $2,240.00 04/17/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411491
Principal investigator 1 PFIZER INC. $1,502.00 04/11/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228829910
Principal investigator 1 PFIZER INC. $4,373.00 04/11/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228830025
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,394.77 04/08/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223277640
Principal investigator 1 ABBVIE INC. $7,326.00 04/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202468950
Principal investigator 1 ABBVIE INC. $13,571.60 04/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202469148
Principal investigator 1 ABBVIE INC. $263.70 04/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202469152
Principal investigator 1 ABBVIE INC. $2,949.70 04/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202469619
Principal investigator 1 ABBVIE INC. $54,504.30 04/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202469623
Principal investigator 1 ABBVIE INC. $1,248.75 04/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202469631
Principal investigator 1 ABBVIE INC. $4,491.30 04/03/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202469635
Principal investigator 1 Janssen Research & Development, LLC $2,575.00 03/31/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175411423
Principal investigator 1 Janssen Research & Development, LLC $11,152.00 03/31/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411454
Principal investigator 1 Janssen Research & Development, LLC $4,142.00 03/27/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411485
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288483
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288579
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288807
Principal investigator 1 Janssen Research & Development, LLC $1,557.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288931
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289262
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289980
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290125
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290170
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290626
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290685
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290833
Principal investigator 1 Janssen Research & Development, LLC $184.00 03/25/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,425.14 03/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223276979
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,151.25 03/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223276981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,079.00 03/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223277009
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287901
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288191
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288416
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289166
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289353
Principal investigator 1 Janssen Research & Development, LLC $343.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289596
Principal investigator 1 Janssen Research & Development, LLC $343.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289884
Principal investigator 1 Janssen Research & Development, LLC $3,228.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290152
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290571
Principal investigator 1 Janssen Research & Development, LLC $3,729.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290610
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/24/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290857
Principal investigator 1 PFIZER INC. $584.00 03/21/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228831614
Principal investigator 1 PFIZER INC. $584.00 03/21/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228831759
Principal investigator 1 PFIZER INC. $584.00 03/21/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228832605
Principal investigator 1 PFIZER INC. $584.00 03/21/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228832698
Principal investigator 1 Janssen Research & Development, LLC $1,654.00 03/20/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175288347
Principal investigator 1 Janssen Research & Development, LLC $5,937.00 03/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288008
Principal investigator 1 Janssen Research & Development, LLC $1,362.00 03/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289641
Principal investigator 1 Janssen Research & Development, LLC $76.00 03/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290693
Principal investigator 1 Janssen Research & Development, LLC $1,362.00 03/19/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,087.15 03/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223276781
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,017.05 03/19/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223276795
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,589.90 03/13/2025 Non-covered Recipient Entity
Tyler Research Institute, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244052557
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,286.47 03/11/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223276161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,952.25 03/11/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223276163
Principal investigator 1 SANOFI US SERVICES INC. $7,800.00 03/10/2025 Non-covered Recipient Entity
Tyler Research Institute Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226121201
Principal investigator 1 ABBVIE INC. $21,941.80 03/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202459455
Principal investigator 1 ABBVIE INC. $2,025.00 03/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202459518
Principal investigator 1 ABBVIE INC. $6,975.85 03/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202462044
Principal investigator 1 Genentech, Inc. $396.00 03/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211674553
Principal investigator 1 ABBVIE INC. $26,122.50 03/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202456629
Principal investigator 1 ABBVIE INC. $11,830.00 03/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202458290
Principal investigator 1 ABBVIE INC. $21,202.40 03/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202458692
Principal investigator 1 Eli Lilly and Company $43,060.00 03/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187893210
Principal investigator 1 SANOFI US SERVICES INC. $6,970.00 03/04/2025 Non-covered Recipient Entity
Tyler Research Institute Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226121197
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,481.92 03/04/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223275925
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287932
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287967
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175287975
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288363
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288475
Principal investigator 1 Janssen Research & Development, LLC $3,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288573
Principal investigator 1 Janssen Research & Development, LLC $3,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288789
Principal investigator 1 Janssen Research & Development, LLC $3,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288836
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289027
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289087
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289111
Principal investigator 1 Janssen Research & Development, LLC $3,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289434
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289446
Principal investigator 1 Janssen Research & Development, LLC $3,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289588
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289747
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289770
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289803
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290182
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290220
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290253
Principal investigator 1 Janssen Research & Development, LLC $3,228.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290264
Principal investigator 1 Janssen Research & Development, LLC $343.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290320
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290329
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290524
Principal investigator 1 Janssen Research & Development, LLC $3,229.00 03/03/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290897
Principal investigator 1 PFIZER INC. $584.00 03/03/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228831664
Principal investigator 1 Janssen Research & Development, LLC $159.00 02/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288689
Principal investigator 1 Janssen Research & Development, LLC $1,955.00 02/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289386
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 02/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289652
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 02/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290104
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 02/28/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290298
Principal investigator 1 Janssen Research & Development, LLC $5,500.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175287917
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288032
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288232
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288240
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288293
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288301
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288341
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288423
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288466
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288554
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288640
Principal investigator 1 Janssen Research & Development, LLC $117.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288698
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288704
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288714
Principal investigator 1 Janssen Research & Development, LLC $124.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288799
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288894
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288902
Principal investigator 1 Janssen Research & Development, LLC $76.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289269
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289295
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289315
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289330
Principal investigator 1 Janssen Research & Development, LLC $836.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289377
Principal investigator 1 Janssen Research & Development, LLC $124.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289480
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289558
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289581
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289633
Principal investigator 1 Janssen Research & Development, LLC $124.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289691
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175289996
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290270
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290361
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290383
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290576
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290669
Principal investigator 1 Janssen Research & Development, LLC $184.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290677
Principal investigator 1 Janssen Research & Development, LLC $335.00 02/26/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290810
Principal investigator 1 Eli Lilly and Company $550.48 02/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187891892
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,343.25 02/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1223275509
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,801.00 02/25/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223275511
Principal investigator 1 Genentech, Inc. $17,544.00 02/21/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211674556
Principal investigator 1 ABBVIE INC. $13,745.40 02/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202453230
Principal investigator 1 ABBVIE INC. $40,196.25 02/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202453234
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,764.55 02/18/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223275355
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 02/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288019
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 02/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288562
Principal investigator 1 Janssen Research & Development, LLC $1,359.00 02/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288861
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 02/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290343
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 02/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290433
Principal investigator 1 Janssen Research & Development, LLC $1,415.00 02/17/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290749
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,500.00 02/13/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223275247
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $48,167.05 02/07/2025 Non-covered Recipient Entity
Tyler Research Institute
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235992841
Principal investigator 1 ABBVIE INC. $1,752.50 02/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202449731
Principal investigator 1 ABBVIE INC. $29,224.85 02/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202449736
Principal investigator 1 ABBVIE INC. $675.00 02/06/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202449770
Principal investigator 1 ABBVIE INC. $7,022.60 02/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202444485
Principal investigator 1 ABBVIE INC. $10,519.60 02/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202446102
Principal investigator 1 ABBVIE INC. $5,281.90 02/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202446154
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,864.50 02/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223274761
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,817.10 02/05/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223274779
Principal investigator 1 PFIZER INC. $584.00 02/03/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228831749
Principal investigator 1 PFIZER INC. $1,173.00 02/03/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228831767
Principal investigator 1 PFIZER INC. $2,471.00 02/03/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228832104
Principal investigator 1 PFIZER INC. $1,173.00 02/03/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228832198
Principal investigator 1 PFIZER INC. $1,173.00 02/03/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228832541
Principal investigator 1 PFIZER INC. $584.00 02/03/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228832599
Principal investigator 1 PFIZER INC. $1,173.00 02/03/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228832692
Principal investigator 1 Janssen Research & Development, LLC $2,425.00 01/31/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and Safety of JNJ-77242113 in Participants No dispute reported 06/30/2026 1175411496
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 01/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175289044
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 01/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175289818
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 01/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175289954
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 01/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290539
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 01/30/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) No dispute reported 06/30/2026 1175290954
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,063.50 01/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223274527
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,583.25 01/29/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223274537
Principal investigator 1 Janssen Research & Development, LLC $3,349.00 01/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175288546
Principal investigator 1 Janssen Research & Development, LLC $3,532.00 01/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289134
Principal investigator 1 Janssen Research & Development, LLC $3,229.00 01/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289207
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 01/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175289944
Principal investigator 1 Janssen Research & Development, LLC $2,632.00 01/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290416
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 01/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290441
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 01/27/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) No dispute reported 06/30/2026 1175290494
Principal investigator 1 SANOFI US SERVICES INC. $4,250.00 01/27/2025 Non-covered Recipient Entity
Tyler Research Institute Llc
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype No dispute reported 06/30/2026 1226121193
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,031.75 01/21/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223274243
Principal investigator 1 Janssen Research & Development, LLC $2,048.00 01/20/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175411416
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,079.00 01/17/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223274015
Principal investigator 1 ABBVIE INC. $3,685.50 01/16/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No dispute reported 06/30/2026 1202439523
Principal investigator 1 Janssen Research & Development, LLC $5,937.00 01/15/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175288822
Principal investigator 1 Janssen Research & Development, LLC $76.00 01/15/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1175290945
Principal investigator 1 PFIZER INC. $11,454.60 01/15/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228831754
Principal investigator 1 Janssen Research & Development, LLC $217.00 01/13/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175288330
Principal investigator 1 Janssen Research & Development, LLC $445.00 01/13/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175289617
Principal investigator 1 Janssen Research & Development, LLC $6,341.00 01/13/2025 Non-covered Recipient Entity
Tyler Rsrch Inst Llc
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175290890
Principal investigator 1 Eli Lilly and Company $10,050.00 01/10/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1187891466
Principal investigator 1 ABBVIE INC. $13,398.75 01/09/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202437814
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,402.75 01/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223273627
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,825.60 01/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223273645
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,873.00 01/07/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223273647
Principal investigator 1 PFIZER INC. $443.00 01/06/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228831670
Principal investigator 1 PFIZER INC. $730.00 01/06/2025 Non-covered Recipient Entity
Tyler Research Institute LLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228832203
Principal investigator 1 ABBVIE INC. $3,645.30 01/02/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202434137
Principal investigator 1 ABBVIE INC. $1,539.30 01/02/2025 Non-covered Recipient Entity
TYLER RESEARCH INSTITUTE LLC
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202435845
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,398.10 01/01/2025 Non-covered Recipient Entity
Tyler Research Institute
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1235992843